Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease

about

Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease

Item

http://www.wikidata.org/entity/Q36220062

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Limited Impact of Imatinib in ...... onic Graft-versus-Host Disease

@ast

Limited Impact of Imatinib in ...... onic Graft-versus-Host Disease

@en

type

Item

label

Limited Impact of Imatinib in ...... onic Graft-versus-Host Disease

@ast

Limited Impact of Imatinib in ...... onic Graft-versus-Host Disease

@en

prefLabel

Limited Impact of Imatinib in ...... onic Graft-versus-Host Disease

@ast

Limited Impact of Imatinib in ...... onic Graft-versus-Host Disease

@en

P1476

Limited Impact of Imatinib in ...... onic Graft-versus-Host Disease

@en

P2093

Frédéric Baron

http://www.w3.org/2001/XMLSchema#string

Gilles Fransolet

http://www.w3.org/2001/XMLSchema#string

Grégory Ehx

http://www.w3.org/2001/XMLSchema#string

Joan Somja

http://www.w3.org/2001/XMLSchema#string

Ludovic Belle

http://www.w3.org/2001/XMLSchema#string

Marilène Binsfeld

http://www.w3.org/2001/XMLSchema#string

Muriel Hannon

http://www.w3.org/2001/XMLSchema#string

Philippe Delvenne

http://www.w3.org/2001/XMLSchema#string

Pierre Drion

http://www.w3.org/2001/XMLSchema#string

Yves Beguin

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission

Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium

Advances in graft-versus-host disease biology and therapy.

Molecules and mechanisms of the graft-versus-leukaemia effect.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age

Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.

P304

e0167997

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0167997

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27942010

http://www.w3.org/2001/XMLSchema#string

P932

5152855

http://www.w3.org/2001/XMLSchema#string